Auris Medical Holding Ag (EARS) 4.65 $EARS
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:45AM CDT
AEC: 28.49 (+4.01), SMCI: 31.90 (-2.91), CAMP: 20.87 (+4.19), GEVO: 2.79 (+0.78), DSKX: 1.64 (+0.30), CCIH: 14.86 (+2.54), ENZN: 1.70 (+0.20), NRP: 5.54 (-1.38), PARN: 4.19 (-0.30), GBSN: 4.98 (+1.44), AMSC: 10.40 (+1.20), PW: 6.33 (-2.95), EARS: 4.65 (-0.75), EMMS: 1.61 (-0.24), COOL: 1.40 (-0.21), LOOK: 1.75 (-0.51), ONVO: 5.14 (+0.67), HMNY: 2.90 (-0.63), PKT: 11.42 (+1.91), ZHNE: 1.89 (+0.36)
Auris Medical off 17% on modest volume
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 10:44AM CDT
EARS: 4.65 (-0.75)
Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals
GlobeNewswire - Mon Apr 20, 3:10PM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced publications related to AM-101, the Company's lead product candidate for the treatment of acute inner ear tinnitus, in two peer-reviewed specialist journals. "We are very pleased to see these important additional pre-clinical and clinical data published on our AM-101 program", commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. "They add further to our understanding of the pathogenesis of inner ear tinnitus as well as AM-101's therapeutic effects and potential clinical use."
EARS: 4.65 (-0.75)
Auris Medical to Propose Election of Two New Board Members at Forthcoming Annual General Meeting
GlobeNewswire - Mon Mar 30, 5:12PM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedi-cated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that its Board of Directors will propose the election of two new members of the Board of Directors at its forthcoming Annual General Meeting:
EARS: 4.65 (-0.75)
LifeSci Capital Initiates Coverage of Auris Medical
ACCESSWIRE - Mon Mar 23, 8:02AM CDT
Focused on Developing First-in-Class Therapeutics for Inner Ear Disorders
EARS: 4.65 (-0.75)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
EVOL: 9.42 (-0.19), FLML: 15.84 (-0.33), EARS: 4.65 (-0.75), FICO: 92.00 (-0.15), CTRN: 24.27 (+0.16)
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:21AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 5% on the day.
EARS: 4.65 (-0.75), GNCA: 12.48 (-0.23)
Bellicum Pharmaceuticals, Inc. (BLCM) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:18AM CDT
Bellicum Pharmaceuticals, Inc. (BLCM) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.65 (-0.75), BLCM: 28.55 (+2.59)
Auris Medical Holding's (EARS) CEO Thomas Meyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 19, 1:50PM CDT
EARS: 4.65 (-0.75)
Auris Medical Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:54AM CDT
EARS: 4.65 (-0.75)
Auris reports 4Q loss
Automated Insights - Thu Mar 19, 6:39AM CDT
4001 BASEL, Switzerland (AP) _ Auris Medical Holding AG (EARS) on Thursday reported a loss of $4 million in its fourth quarter.
EARS: 4.65 (-0.75)
Auris Medical beats by $0.18
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:12AM CDT
EARS: 4.65 (-0.75)
Auris Medical Holding AG Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 19, 6:08AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today provided an update on the Company's business and announced financial results for the fourth quarter and financial year ended December 31, 2014.
EARS: 4.65 (-0.75)
Tinnitus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Mar 17, 11:30AM CDT
The report "Tinnitus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tinnitus. Tinnitus is the medical term for "hearing" noises in your ears when there is no outside source of the sounds. It can make verbal communication impossible and can cause depression. Depending on the type of tinnitus, symptoms will tend to come and go over time. Stress level, diet, and exposure to noise can worsen tinnitus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tinnitus-pip...eport.html .
FLXN: 18.77 (-0.78), EARS: 4.65 (-0.75), OTIC: 32.83 (unch)
Auris Medical to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Thursday, March 19, 2015
GlobeNewswire - Mon Mar 16, 7:46AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today announced that it will release its financial results for the fourth quarter and full year 2014, on Thursday, March 19, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (1:00 p.m. Central European Time) to discuss Auris Medical's financial results for the fourth quarter and full year 2014 and provide a general business update.
EARS: 4.65 (-0.75)
Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus
GlobeNewswire - Fri Mar 13, 6:05AM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has recently been granted a patent by the Indian patent office covering the use of its investigational tinnitus treatment AM-101. India patent No. 264994 describes methods for the treatment of tinnitus induced by cochlear excitotoxicity, and notably the use of Ketamine and related compounds for that purpose.
EARS: 4.65 (-0.75)
Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City
GlobeNewswire - Wed Mar 11, 6:06AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a Key Opinion Leader breakfast focused on current advances in tinnitus treatments. The event and live webcast will take place on Friday, March 13 from 8:00am-9:30am Eastern Time in New York City.
EARS: 4.65 (-0.75)
Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101
GlobeNewswire - Tue Mar 10, 7:23AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the completion of the planned interim analysis in the post-acute tinnitus stratum of the TACTT3 trial ("Stratum B"
with AM-101 and that enrollment could continue since the pre-specified futility threshold was not reached. Based on recommendations by the Independent Data Review Committee, the inclusion criteria will be adapted in order to focus on the early post-acute stage where higher levels of activity were observed than at the later stage. Accordingly, Stratum B will continue to enroll patients with tinnitus having started between 3 and 6 months prior and stop enrollment of patients with onset 6 to 12 months prior. The TACTT2 trial and Stratum A of TACTT3, which enroll patients with tinnitus up to 3 months from onset and were not part of the interim analysis, will continue unchanged.
EARS: 4.65 (-0.75)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:45AM CDT
AEC: 28.49 (+4.01), SMCI: 31.90 (-2.91), CAMP: 20.87 (+4.19), GEVO: 2.79 (+0.78), DSKX: 1.64 (+0.30), CCIH: 14.86 (+2.54), ENZN: 1.70 (+0.20), NRP: 5.54 (-1.38), PARN: 4.19 (-0.30), GBSN: 4.98 (+1.44), AMSC: 10.40 (+1.20), PW: 6.33 (-2.95), EARS: 4.65 (-0.75), EMMS: 1.61 (-0.24), COOL: 1.40 (-0.21), LOOK: 1.75 (-0.51), ONVO: 5.14 (+0.67), HMNY: 2.90 (-0.63), PKT: 11.42 (+1.91), ZHNE: 1.89 (+0.36)
Auris Medical off 17% on modest volume
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 10:44AM CDT
EARS: 4.65 (-0.75)
Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals
GlobeNewswire - Mon Apr 20, 3:10PM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced publications related to AM-101, the Company's lead product candidate for the treatment of acute inner ear tinnitus, in two peer-reviewed specialist journals. "We are very pleased to see these important additional pre-clinical and clinical data published on our AM-101 program", commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. "They add further to our understanding of the pathogenesis of inner ear tinnitus as well as AM-101's therapeutic effects and potential clinical use."
EARS: 4.65 (-0.75)
Auris Medical to Propose Election of Two New Board Members at Forthcoming Annual General Meeting
GlobeNewswire - Mon Mar 30, 5:12PM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedi-cated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that its Board of Directors will propose the election of two new members of the Board of Directors at its forthcoming Annual General Meeting:
EARS: 4.65 (-0.75)
LifeSci Capital Initiates Coverage of Auris Medical
ACCESSWIRE - Mon Mar 23, 8:02AM CDT
Focused on Developing First-in-Class Therapeutics for Inner Ear Disorders
EARS: 4.65 (-0.75)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
EVOL: 9.42 (-0.19), FLML: 15.84 (-0.33), EARS: 4.65 (-0.75), FICO: 92.00 (-0.15), CTRN: 24.27 (+0.16)
Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:21AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 5% on the day.
EARS: 4.65 (-0.75), GNCA: 12.48 (-0.23)
Bellicum Pharmaceuticals, Inc. (BLCM) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:18AM CDT
Bellicum Pharmaceuticals, Inc. (BLCM) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.65 (-0.75), BLCM: 28.55 (+2.59)
Auris Medical Holding's (EARS) CEO Thomas Meyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 19, 1:50PM CDT
EARS: 4.65 (-0.75)
Auris Medical Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:54AM CDT
EARS: 4.65 (-0.75)
Auris reports 4Q loss
Automated Insights - Thu Mar 19, 6:39AM CDT
4001 BASEL, Switzerland (AP) _ Auris Medical Holding AG (EARS) on Thursday reported a loss of $4 million in its fourth quarter.
EARS: 4.65 (-0.75)
Auris Medical beats by $0.18
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:12AM CDT
EARS: 4.65 (-0.75)
Auris Medical Holding AG Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 19, 6:08AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today provided an update on the Company's business and announced financial results for the fourth quarter and financial year ended December 31, 2014.
EARS: 4.65 (-0.75)
Tinnitus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Mar 17, 11:30AM CDT
The report "Tinnitus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tinnitus. Tinnitus is the medical term for "hearing" noises in your ears when there is no outside source of the sounds. It can make verbal communication impossible and can cause depression. Depending on the type of tinnitus, symptoms will tend to come and go over time. Stress level, diet, and exposure to noise can worsen tinnitus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tinnitus-pip...eport.html .
FLXN: 18.77 (-0.78), EARS: 4.65 (-0.75), OTIC: 32.83 (unch)
Auris Medical to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Thursday, March 19, 2015
GlobeNewswire - Mon Mar 16, 7:46AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today announced that it will release its financial results for the fourth quarter and full year 2014, on Thursday, March 19, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (1:00 p.m. Central European Time) to discuss Auris Medical's financial results for the fourth quarter and full year 2014 and provide a general business update.
EARS: 4.65 (-0.75)
Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus
GlobeNewswire - Fri Mar 13, 6:05AM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has recently been granted a patent by the Indian patent office covering the use of its investigational tinnitus treatment AM-101. India patent No. 264994 describes methods for the treatment of tinnitus induced by cochlear excitotoxicity, and notably the use of Ketamine and related compounds for that purpose.
EARS: 4.65 (-0.75)
Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City
GlobeNewswire - Wed Mar 11, 6:06AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a Key Opinion Leader breakfast focused on current advances in tinnitus treatments. The event and live webcast will take place on Friday, March 13 from 8:00am-9:30am Eastern Time in New York City.
EARS: 4.65 (-0.75)
Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101
GlobeNewswire - Tue Mar 10, 7:23AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the completion of the planned interim analysis in the post-acute tinnitus stratum of the TACTT3 trial ("Stratum B"
with AM-101 and that enrollment could continue since the pre-specified futility threshold was not reached. Based on recommendations by the Independent Data Review Committee, the inclusion criteria will be adapted in order to focus on the early post-acute stage where higher levels of activity were observed than at the later stage. Accordingly, Stratum B will continue to enroll patients with tinnitus having started between 3 and 6 months prior and stop enrollment of patients with onset 6 to 12 months prior. The TACTT2 trial and Stratum A of TACTT3, which enroll patients with tinnitus up to 3 months from onset and were not part of the interim analysis, will continue unchanged. EARS: 4.65 (-0.75)
